ArticleThe Lancet. Oncology2015
Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.
Article in The Lancet. Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways.Medical oncology (Northwood, London, England) · 2024Pooled it
- Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.Nature medicine · 2024Trial
- Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.Cancer communications (London, England) · 2018Trial
- Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Article
- Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis.Frontiers in genetics · 2024Article
- The clonal expression genes associated with poor prognosis of liver cancer.Frontiers in genetics · 2022Article
- Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma.Journal of oncology · 2022Article
- Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection.Frontiers in oncology · 2021Article
- Targeting angiogenesis for liver cancer: Past, present, and future.Genes & diseases · 2020Review
- Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects.Genes & diseases · 2020Review
- Targeted therapy for hepatocellular carcinoma.Signal transduction and targeted therapy · 2020Review
- Emerging agents and regimens for hepatocellular carcinoma.Journal of hematology & oncology · 2019Review
- Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
- Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications.Clinical and translational gastroenterology · 2019Review
- Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.International journal of oncology · 2016Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.